tetano
Editor, Senior Moderator
J Clin Med
. 2021 Mar 4;10(5):1051.
doi: 10.3390/jcm10051051.
Arginase 1 ( Arg1) as an Up-Regulated Gene in COVID-19 Patients: A Promising Marker in COVID-19 Immunopathy
Afshin Derakhshani[SUP] 1 [/SUP], Nima Hemmat[SUP] 1 [/SUP], Zahra Asadzadeh[SUP] 1 [/SUP], Moslem Ghaseminia[SUP] 2 [/SUP], Mahdi Abdoli Shadbad[SUP] 1 3 [/SUP], Golamreza Jadideslam[SUP] 4 [/SUP], Nicola Silvestris[SUP] 5 6 [/SUP], Vito Racanelli[SUP] 6 [/SUP], Behzad Baradaran[SUP] 1 7 [/SUP]
Affiliations
Abstract
Background: The coronavirus disease 2019 (COVID-19) outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a global pandemic. It is well-established that SARS-CoV-2 infection can lead to dysregulated immune responses. Arginase-1 (Arg1), which has a pivotal role in immune cells, can be expressed in most of the myeloid cells, e.g., neutrophils and macrophages. Arg1 has been associated with the suppression of antiviral immune responses.
Methods: Whole blood was taken from 21 COVID-19 patients and 21 healthy individuals, and after RNA extraction and complementary DNA (cDNA) synthesis, gene expression of Arg1 was measured by real-time PCR.
Results: The qPCR results showed that the expression of Arg1 was significantly increased in COVID-19 patients compared to healthy individuals (p < 0.01). The relative expression analysis demonstrated there were approximately 2.3 times increased Arg1 expression in the whole blood of COVID-19 patients. Furthermore, the receiver operating characteristic (ROC) analysis showed a considerable diagnostic value for Arg1 expression in COVID-19 (p = 0.0002 and AUC = 0.8401).
Conclusion: Arg1 might be a promising marker in the pathogenesis of the disease, and it could be a valuable diagnostic tool.
Keywords: Arg1; COVID-19; SARS-CoV-2; antiviral immunity; global pandemic.
. 2021 Mar 4;10(5):1051.
doi: 10.3390/jcm10051051.
Arginase 1 ( Arg1) as an Up-Regulated Gene in COVID-19 Patients: A Promising Marker in COVID-19 Immunopathy
Afshin Derakhshani[SUP] 1 [/SUP], Nima Hemmat[SUP] 1 [/SUP], Zahra Asadzadeh[SUP] 1 [/SUP], Moslem Ghaseminia[SUP] 2 [/SUP], Mahdi Abdoli Shadbad[SUP] 1 3 [/SUP], Golamreza Jadideslam[SUP] 4 [/SUP], Nicola Silvestris[SUP] 5 6 [/SUP], Vito Racanelli[SUP] 6 [/SUP], Behzad Baradaran[SUP] 1 7 [/SUP]
Affiliations
- PMID: 33806290
- DOI: 10.3390/jcm10051051
Abstract
Background: The coronavirus disease 2019 (COVID-19) outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a global pandemic. It is well-established that SARS-CoV-2 infection can lead to dysregulated immune responses. Arginase-1 (Arg1), which has a pivotal role in immune cells, can be expressed in most of the myeloid cells, e.g., neutrophils and macrophages. Arg1 has been associated with the suppression of antiviral immune responses.
Methods: Whole blood was taken from 21 COVID-19 patients and 21 healthy individuals, and after RNA extraction and complementary DNA (cDNA) synthesis, gene expression of Arg1 was measured by real-time PCR.
Results: The qPCR results showed that the expression of Arg1 was significantly increased in COVID-19 patients compared to healthy individuals (p < 0.01). The relative expression analysis demonstrated there were approximately 2.3 times increased Arg1 expression in the whole blood of COVID-19 patients. Furthermore, the receiver operating characteristic (ROC) analysis showed a considerable diagnostic value for Arg1 expression in COVID-19 (p = 0.0002 and AUC = 0.8401).
Conclusion: Arg1 might be a promising marker in the pathogenesis of the disease, and it could be a valuable diagnostic tool.
Keywords: Arg1; COVID-19; SARS-CoV-2; antiviral immunity; global pandemic.